Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS in Kidney Transplantation
NCT02475551Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Jun 2015
- Primary completion
- Oct 2016
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imlifidase in end-stage kidney disease (ESKD), sponsored by Hansa Biopharma. Primary endpoint: Safety at 6 months. Started Jun 2015; status: completed.
02
Drugs
imlifidase
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT02475551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475551.